BOUCHERVILLE, Quebec, May 22, 2024 (GLOBE NEWSWIRE) — LSL PHARMA GROUP INC. (TSXV: LSL) (the “Corporation” or “LSL Pharma “), a Canadian integrated pharmaceutical company, is pleased to announce that the Convertible Unsecured Redeemable Debentures (the “Debentures”) issued pursuant to a $3.288 million brokered private placement completed in tranches on November 1, 2023 and December 8, 2023 have been approved for listing on the TSXV under the symbol “LSL.DB” and will begin trading on May 24, 2024.
- Pixalate’s January 2025 Top Grossing Mobile and CTV Apps in the U.S. and Canada: ‘Pocket FM’ Ranked No. 1 on Google Play Store ($4M) in the U.S.; ‘Hulu’ No. 1 With $162M Across Roku, Amazon Fire TV, Samsung TV, & Apple TV - February 12, 2025
- RIZON Expands Electric Fleet Offerings in Canada with Premier Truck Group of Mississauga - February 12, 2025
- Atmos Energy Recognized on Forbes “America’s Best Employers” List for Fifth Consecutive Year - February 12, 2025